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Background: Inherited epidermolysis bullosa (EB) is a group of skin diseases characterized by blistering of the skin
and mucous membranes.
There are four major types of EB (EB simplex, junctional EB, dystrophic EB and Kindler syndrome) caused by
different gene mutations. Dystrophic EB is derived from mutations in the type VII collagen gene (COL7A1),
encoding a protein which is the predominant component of the anchoring fibrils at the dermal-epidermal junction.
For the first time in literature, we have evaluated the presence of anti-skin autoantibodies in a wider cohort of
patients suffering from inherited EB and ascertained whether they may be a marker of disease activity.
Methods: Sera from patients with inherited EB, 17 with recessive dystrophic EB (RDEB), 10 with EB simplex (EBS)
were analysed. As much as 20 patients with pemphigus vulgaris, 21 patients with bullous pemphigoid and 20
healthy subjects were used as controls.
Anti-skin autoantibodies were tested in all samples with the Indirect Immunofluorescence (IIF) method and the
currently available ELISA method in order to detect anti-type VII collagen, anti-BP180 and anti-BP230 autoantibodies.
Results: The mean concentrations of anti-type VII collagen autoantibodies titres, anti-BP180 and anti-BP230
autoantibodies were statistically higher in RDEB patients than in EBS patients.
The sensitivity and specificity of the anti-type VII collagen ELISA test were 88.2% and 96.7%. The Birmingham
Epidermolysis Bullosa Severity score, which is used to evaluate the severity of the disease, correlated with anti-skin
autoantibodies titres.
Conclusions: The precise pathogenic role of circulating anti-skin autoantibodies in RDEB is unclear. There is a
higher prevalence of both anti-type VII collagen and other autoantibodies in patients with RDEB, but their presence
can be interpreted as an epiphenomenon.
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Epidermolysis bullosa (EB) is a group of both acquired
and inherited diseases characterized by blistering of the
skin and mucous membranes, in response to little or no
apparent trauma [1].
In inherited EB, the phenotypic manifestations of this
disease can be very different; in the milder forms, there
is a lifelong blistering tendency with no impact on the
overall longevity of the affected subject, while in the
most severe forms children die during the early postna-
tal period from metabolic perturbations, dehydration,
and sepsis [2].
Inherited EB has typically been classified into four
main subtypes; these differ not only phenotypically and
genotypically but, more importantly, by the site of ultra-
structural distruption or cleavage. Tissue separation oc-
curs within the intraepidermal keratinocyte cytoplasm in
EB simplex (EBS), through the lamina lucida in junc-
tional EB (JEB) or in the sublamina densa in dystrophic
EB (DEB) [3]; in Kindler syndrome, multiple cleavage
planes may be seen within the same sample of skin [4].
Inherited EB is now known to result from more than
1100 mutations, encompassing more than 14 distinct
structural genes expressed within the cutaneous base-
ment membrane zone (BMZ) at the dermoepidermal
junction [5,6]. After the initial clinical evaluation, based
on careful examination of cutaneous and extracutaneous
manifestations and inheritance pattern, the diagnosis is
confirmed by the use of three main techniques: im-
munofluorescence mapping (IFM), transmission electron
microscopy (TEM), which can both be used to identify
the level of skin cleavage, and mutation analysis [7]. TEM
is considered the gold standard laboratory test for differ-
entiation between the various forms of EB. The primary
advantage is that it can visualize ultra-structural abnor-
malities and may be particularly useful in patients with
mild DEB or EBS. However, TEM is time-consuming and
expensive, and the results are, to a high degree, operator-
dependent and sometimes inaccurate [8]. The diagnostic
precision of IFM is similar to that of TEM, with the ad-
vantage that it is simpler and faster both to perform and
to interpret. A previous study has shown that IFM is more
sensitive (97% vs. 71%) and specific (100% vs. 81%) than
TEM [9].
Mutation analysis is an excellent technique to confirm
the diagnosis for the various subtypes of EB as well as to
provide information that might be useful for prenatal
diagnosis and someday for genetic therapy [10].
Dystrophic EB and type VII collagen
Dystrophic EB (DEB) forms, also known as dermolytic
forms, are characterized by tense blisters and erosions
that heal with extensive, either atrophic or hypertrophic,
scarring. The scarring tendency reflects the fact thatblister formation occurs below the level of the lamina
densa of the BMZ of the papillary derma. The spectrum of
clinical severity in DEB is, however, highly variable, with
milder forms of the disease showing a limited tendency to
blistering or nail involvement and severe forms where the
gastrointestinal tract, particularly the oesophagus, is af-
fected by blistering and scarring. All forms result from
mutations within type VII collagen gene, COL7A1 [10].
The type VII collagen, the main constituent of the
anchoring fibrils, is composed of a triple-helical domain
flanked by a large 145 kDa non-collagenous amino-
terminal (NC-1) domain and a small 34 kDa non-
collagenous carboxyl-terminal (NC-2) domain [11,12]. In
patients with DEB, ultrastructural analysis of skin dem-
onstrates the presence of altered anchoring fibrils, re-
duced in number or completely absent in the different
forms [13].
Autoantibodies against type VII collagen
In addition to inherited forms of EB, there is an acquired
form of epidermolysis bullosa (EBA), which is caused by
an auto-reactive response against collagen VII. Patients
with EBA have both tissue-bound and circulating IgG
autoantibodies against type VII collagen [14,15]. Specif-
ically, circulating autoantibodies recognize epitopes
within the amino-terminal NC-1 domain of type VII col-
lagen [16,17]; only a small number of EBA patients have
been described with autoantibodies reactivity against the
NC-2 domain [18]. The routine screening tests for the
diagnosis of EBA are: direct and indirect immunofluores-
cence microscopy; in particular, the salt-split skin method.
Patients with EBA have immune deposits on the dermal
side of salt-split skin, whereas in bullous pemphigoid (BP)
deposits are on the epidermal side. However, this method
does not distinguish EBA from anti-laminin 332 mucous
membrane pemphigoid (MMP) or anti-laminin c1 pem-
phigoid as these diseases also show immune deposition on
the dermal side of salt-split skin. EBA sera recognize the
290 kDa type VII collagen protein in immunoblotting
studies; in fact, this reactivity confirms the diagnosis of
EBA. However, immunoblotting studies are difficult to
carry out because they are time-consuming and technic-
ally demanding. Advances in the identification of target
antigens and the subsequent development of an increasing
number of sensitive and specific assays for the detection
of circulating autoantibodies, including recombinant
forms of the target antigens and ELISA, allow serological
diagnosis in patients with autoimmune skin disorders.
Several ELISA systems using recombinant fragments of
BP180, BP230, desmoglein1, desmoglein3, have become
commercially available and are highly valuable diagnostic
tools [19]. ELISAs were also developed to detect autoanti-
bodies in EBA using different recombinant proteins of
the NC-1 domain of type VII collagen [20,21]. Previous
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ity and specificity, and in some clinical studies serial titres
of anti-type collagen VII from each patient with EBA
reflected the disease activity [22-24]. Experimental studies
provided evidence that autoantibodies against type VII
collagen are pathogenic. When rabbit and human anti-
bodies were passively transferred into mice, they induced
subepidermal blister formation and nail dystrophy [25,26].
The active mouse model of EBA was also established by
immunizing mice with the recombinant NC-1 domain of
murine type VII collagen [27].
Although DEB has been shown to result from muta-
tions in COL7A1, relatively little is known about the
mechanistic consequences of the mutations in relation
to blistering. To facilitate our understanding of DEB, we
have evaluated the presence of anti-skin autoantibodies
in a wider cohort of patients suffering from DEB and




Serum samples were obtained from 27 patients with
inherited forms of EB, seen at the Dermatological
Department of the University Hospital in Bari between
January 2010 and December 2012. All patients exam-
ined had typical clinical features of EB with a variable
phenotype as well as immunofluorescence mapping and
transmission electron microscopy findings consistent
with EB.
As many as 17 patients had recessive dystrophic EB
(RDEB), mean age 21.2 years, range 2-50, 4 male and 13
female; 10 patients had EB simplex (EBS), mean age
17 years, range 1-56, 3 male and 7 female. In all patients,
disease severity was evaluated through the Birmingham
Epidermolysis Bullosa Severity score (BEBS), which in-
cludes 11 items: area of damaged skin, involvement of
nails, mouth, eyes, larynx and oesophagus, scarring of
hands, skin cancer, chronic wounds, alopecia and nutri-
tional compromise. Area was allocated 50 points, and
the 10 other items 5 points each, giving a maximum
score of 100 [28]. The BEBS score was performed by a
dermatology specialist at blood sample collection.
Diseases control sera were obtained from 41 patients,
including 20 patients with pemphigus vulgaris (PV) (mean
age 59 years, range 37-85, 6 males, 14 females) and from
21 patients with bullous pemphigoid (BP) (mean age
74 years, range 61-90, 9 males, 12 females).
Control sera were obtained from 20 healthy subjects
(mean age 47 years, range 36-65, 6 males and 14 females).
All sera were stored at -20°C until assayed.
Patients and control subjects gave written consent to
participate in this study, and the Ethics Committee of
the hospital approved this study.Methods
The detection of circulating anti-skin autoantibodies was
performed in all samples with an Indirect Immunofluores-
cence (IIF) method (Euroimmun, Lubeck, Germany) and
with the currently commercially available ELISA methods
(MBL, Nagoya, Japan). Anti-type VII collagen ELISA kits
were provided free of charge by the manufacturer. All
assays were performed at the Laboratory of Clinical
Pathology in the University Hospital of Bari.
IIF method
Slides were made of frozen primate oesophagus section.
IIF assays were performed at a serum dilution of 1:10 in
phosphate buffered saline (pH 7.3).
Two different fluorescence patterns can be observed
on primate esophagus sections: a) anti-intercellular sub-
stance (ICS) and anti-basal membrane zone (BMZ). ICS
antibodies, which are specific for pemphigus, are di-
rected against prickle cell desmosomes and react with
surface antigens of keratinocytes; on tissue sections
they display a granular fluorescence of the intercellu-
lar matter in the whole stratum spinosum. BMZ auto-
antibodies, which are specific for pemphigoid diseases
or epidermolysis bullosa acquisita, are directed against
epidermal basal membrane and generate a fine linear
colouring between the stratum basale and the connective
tissue.
Samples were scored positive if a fluorescence reaction
was observed at 1:10 sample dilution.
ELISA methods
Autoantibodies detection was performed in all samples
with the ELISA systems, each one employing different
antigenic proteins coated on the wells of microplates.
Assays were run according to the manufacturers’
instructions.
Patients and control sera, diluted 1:100, were added to
each well of a microwell plate. For detection of anti-type
VII collagen autoantibodies the microplates were coated
with human recombinant NC-1 and NC-2 proteins;
for detection of anti-BP180 and anti-BP230 autoanti-
bodies, the microplates were coated with recombinant
purified BP180-NC16A antigen and recombinant purified
BP230-N and BP230-C antigens, respectively. Sera were
incubated for 1 hour at RT. After washing to remove
any unbound serum proteins, horseradish peroxidise-
conjugated anti-human IgG was added and incubated
for 1 hour at RT. After another washing step, the peroxidise
substrate was added and incubated for 30 min at RT.
The acid solution was then added to each well to ter-
minate the enzyme reaction and stabilize the colour
development. The value in each sample was obtained
by comparing the optical density (OD) of the sample
with the OD of the calibrator.
Tampoia et al. Orphanet Journal of Rare Diseases 2013, 8:132 Page 4 of 10
http://www.ojrd.com/content/8/1/132Statistical analysis
To assess the relationship between clinical features and
autoantibodies titres, we divided inherited EB patients into
EB simplex (EBS) patients and EB recessive dystrophic
(RDEB) patients.
The Kruskal Wallis test was used to compare the titres
of each autoantibody assayed by the ELISA methods in
patients and in the control group.
A P-value below 0.05 was considered statistically sig-
nificant. The Unpaired T test was used to compare the
mean autoantibodies titres between EBS patients and
RDEB patients.
The diagnostic sensitivity of ELISA for anti-type VII
collagen autoantibodies was calculated in 17 patients
with RDEB, and the specificity was calculated in 10
patients with EBS, in 41 control patients with other
diseases and in 20 healthy subjects. The cut-off value
for positivity was validated and optimised by Receiver
Operating Characteristics (ROC).
Correlation analyses were performed by using the
Pearson test.
MedCalc software (Mariakerke, Belgium) was used for
statistical and ROC curve analysis.
Results
Analytical measurements
In patients with EB, the IIF method did not show an
anti-basal membrane zone (BMZ) pattern, as expected.
In the present study, all samples were tested at 1:10, in
accordance to the recommendations for qualitative IIF
given by the manufacturer. However, as the use of only a
single dilution may lead to blocking or masking effects
in high-titered sera, thus causing false-negative results, sera
were retested at 1:100 dilution. At this dilution, no prozone
effects were noted, confirming that those sera were true
negatives. Detection of antibodies by ELISA test allowed
quantitative measurements of autoantibodies serum titres.
Figure 1 shows that the mean concentration of anti-type
VII collagen autoantibodies titres was statistically higher in
patients with RDEB than in patients with EBS, in controls
with other diseases and in healthy subjects (test Kruskal
Wallis, P < 0.0001). Clinical and serological findings of pa-
tients with two different inherited types of EB are reported
in Table 1.
The mean concentrations of anti-type VII collagen auto-
antibodies titres were statistically higher in patients with
RDEB than in patients with EBS (P =0.0014). The mean
concentrations of anti-BP180 and anti-BP230 autoanti-
bodies were also statistically higher in patients with RDEB
than in patients with EBS (P = 0.0028 and P = 0.0023,
respectively).
The area under the curve (AUC) for anti-type VII
collagen ELISA test was 0.931(CI, 0.850-0.976) and ROC
analysis showed that anti-type VII collagen autoantibodieshad a sensitivity of 88.2% (CI, 63.5 -98.2) and a speci-
ficity of 96.7% (CI, 88.6-99.5), using a cut-off value of
5 UA/mL (Figure 2). The prevalence of anti-type VII
collagen autoantibodies was 88% in patients with
RDEB and 10% in patients with EBS. The combined
prevalence of anti-BP180 and anti-BP230 autoantibodies
was 88% in patients with RDEB and 50% in patients
with EBS.
Thus, in RDEB forms there was a higher prevalence
of both anti-type VII collagen autoantibodies and
autoantibodies against BMZ antigens, in particular
BP180 and BP230 (chi-square, P < 0.0001; OR 79.95%
IC 4.01-1575).
Analytical and clinical correlations
ELISA results for each autoantibody and BEBS score for
each patient are reported in Table 2.
In all patients with RDEB, anti-type VII collagen
autoantibodies titres significantly correlated with both
anti-BP180 (slope < 0.0009, R2 0.53) (Figure 3A) and
anti-BP230 (slope < 0.0001, R2 0.83) autoantibodies titres
(Figure 3B).
Birmingham Epidermolysis Bullosa Severity score (BEBS)
correlated with anti-type VII collagen autoantibodies
titres (P = 0.0190) (Figure 4A) and also with anti-BP180
and anti-BP230, P = 0.0119 and P = 0.0097, respectively
(Figure 4B and 4C).
Discussion
Over the last years, the great worldwide interest in in-
herited EB has led to the publication of studies concerning
EB clinical features and its genetic correlation, which are
important for the disease classification and the prediction
of organ involvement. However, no studies about se-
rological features of patients with different subtypes of
inherited EB are available. Recently, recombinant proteins
have been used as antigenic targets in ELISA methods for
detection of anti-skin autoantibodies. These methods have
also confirmed that the sensitivity and the specificity are
analogous to those of the method of reference.
In our study, we analysed for the first time in the lit-
erature the presence of circulating anti-skin autoanti-
bodies in patients suffering from RDEB and EBS. In other
autoimmune blistering skin diseases (as pemphigus and
pemphigoid), it has been shown that anti-skin specific
autoantibodies can take part in the formation process of
the bullous lesion [19]. Regarding EBA, the cross-reacting
autoantibodies are responsible for the incorrect assembly
of type VII collagen into anchoring fibrils, thus altering
both the natural maintenance and turnover of fibrils or
interfering with the ability of the anchoring fibrils to at-
tach to the basement membrane at dermal level [29].
The pathogenic role of these autoantibodies has been
demonstrated in experimental models [30].
100
RDEB EBS PV BP HS
Figure 1 Distribution of anti-type VII collagen autoantibodies titres. Distribution of anti-type VII collagen autoantibodies titres, expressed in
Units/mL in patients with recessive dystrophic epidermolysis bullosa (RDEB), epidermolysis bullosa simplex (EBS), pemphigus vulgaris (PV), bullous
pemphigoid (BP) and healthy subjects (HS). Kruskal Wallis test, P < 0.0001.
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istic consequences of the mutations in relation to blister-
ing, which has led us to look for autoantibodies directed
against cutaneous structures also in these patients. Some
very interesting data have emerged from our study about
the prevalence of anti-skin positivity in patients with
RDEB.
The relationship between a monogenic disease and
autoimmunity is difficult to clarify; we tried to explain it
through different hypothesis.
In RDEB patients, a possible explanation for the de-
velopment of autoantibodies recognizing type VII colla-
gen epitopes could be based on an altered immunologicTable 1 Clinical and serological findings in patients with
recessive dystrophic epidermolysis bullosa (RDEB) and





Patients, no. 17 10
Mean Age 21 17
Range years 2-50 1-56
Males/Females 4/13 3/7
Birmingham severity score
Birmingham severity score, mean 55 5.4
Birmingham severity score, range 5-90 2-36
Autoantibodies titres, mean concentrations P*
-Anti-type VII collagen (U/mL) 27.8 2.5 0.0014
-Anti-BP180 (U/mL) 59.4 8.3 0.0028
-Anti-BP230 (U/mL) 51.2 6.6 0.0023
* Unpaired T Test, P-value < 0.05 was considered statistically significant.recognition of "self" consequence of altered proteins syn-
thesis due to genetic mutation.
We know that autoimmune diseases are characterized
by aberrant immune responses against healthy cells and
tissues, in which a given individual's genetic susceptibil-
ity may play a central role. However, the exact mecha-
nisms underlying the development of these conditions
remain for the most part unknown. In recent years, grow-













Figure 2 ROC analysis of anti-type VII collagen IgG. Receiver-
operating-characteristic (ROC) plot analysis of anti-type VII collagen
IgG autoantibodies. AUC, area under the curve, was 0.931. The
continuous line refers to the ELISA method used.
Table 2 ELISA data for each autoantibody and BEBS score for each patient with recessive dystrophic epidermolysis
bullosa (RDEB) and with epidermolysis bullosa simplex (EBS)
Autoantibodies anti-skin
n. pt Sex Age years tipe EB Anti-BP180 Anti-BP230 Anti-coll VII BEBS score
1 M 20 RDEB 68,8 45,2 27,9 65
2 M 12 RDEB 36 26,7 20,1 67
3 F 4 RDEB 23,5 20,3 8,5 56
4 F 6 EBS 14,7 13,8 2,1 2
5 F 19 RDEB 37,5 37,8 14,9 63
6 F 45 RDEB 6,8 3,3 1,1 39
7 M 34 RDEB 93 53,4 24,5 79
8 M 34 EBS 2,9 3,2 1,3 2
9 F 10 EBS 3,5 3,5 1,2 2
10 F 27 RDEB 1,4 110 53,5 89
11 F 15 RDEB 77,8 69,8 44,4 60
12 F 29 RDEB 151,8 144,5 48,6 82
13 F 29 RDEB 34,5 18,2 5,9 53
14 M 9 RDEB 16,8 13,9 5,8 55
15 F 7 RDEB 76,7 57,9 29,9 53
16 F 7 EBS 13,4 3,5 1,4 2
17 F 7 EBS 10,1 6,3 1,9 2
18 F 33 RDEB 107,6 65,9 45,3 90
19 M 19 EBS 2,7 4,1 1,2 2
20 F 56 EBS 15,1 13,1 10,8 36
21 F 50 RDEB 2,8 3,3 1,2 11
22 F 16 RDEB 161 120,7 76,7 71
23 F 10 RDEB 58,2 52,8 36,6 52
24 F 17 EBS 4,5 8,9 2,1 2
25 M 13 EBS 15,1 8,4 2,2 2
26 F 2 RDEB 56 27,1 12,4 34
27 F 1 EBS 1 1,2 1,4 2
Figure 3 Correlation between anti-type VII collagen autoantibodies titres and the other two anti-skin autoantibodies. (A) Correlation
between anti-type VII collagen autoantibodies titres and anti-BP180 autoantibodies. Pearson test, P < 0.0009, R2 0.53. (B) Correlation between anti-
type VII collagen autoantibodies titres and anti-BP230 autoantibodies. Pearson test, P < 0.0001, R2 0.83.
































































































































Figure 4 Correlation between anti-skin autoantibodies and Birmingham Epidermolysis Bullosa Severity score. (A) Correlation between
anti-type VII collagen autoantibodies titres and BEBS score. (B) Correlation between anti- anti-BP180 autoantibodies titres and BEBS score.
(C) Correlation between anti-BP230 autoantibodies titres and BEBS score. Red points indicate EBS patients; black points indicate RDEB patients.
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in the pathogenesis of autoimmunity; in particular, epigen-
etics. Epigenetics is defined as stable and heritable pat-
terns of gene expression that do not entail any alterations
to the original DNA sequence. Epigenetic mechanisms
primarily consist of DNA methylation, histone modifica-
tions and small non-coding RNA transcripts [31].
Another hypothesis for this autoimmune condition
may relate to the "molecular mimicry", based on the as-
sumption that a foreign antigen holds similar sequence
or structure with self-antigens. Molecular mimicry has
typically been characterized at antibody or T cell level.
Moreover, the exposure to antigen protein derived from
bacterial and viral infection can induce this phenomenon
with the activation of T and B cells [32]. RDEB patients,
as a consequence of chronic wound formation, are often
exposed to bacterial infection; therefore, molecular mim-
icry is likely to occur. However, it is possible that the
initial insult to the anchoring fibrils, mediated by an anti-
body recognizing a single epitope, could lead to the expos-
ure of additional epitopes and subsequent development of
polyvalent antisera.
However, it has recently been shown that the reactivity
versus the NC-1 and NC-2 domains of type VII collagen
protein is more predictive of an inflammatory rather
than an autoimmune disease. This hypothesis is sup-
ported by the presence of anti-type VII collagen auto-
antibodies in inflammatory diseases involving the
intestine, where the presence of this protein has been
demonstrated but not featured by skin blistering such as
Crohn’s disease and inflammatory bowel disease. How-
ever, the correlation between the presence of those anti-
bodies and their pathogenic significance in that illness
remains elusive [33,34]. It has recently been reported
that the major determinant of autoantibody pathogen-
icity relies on the different IgG subclass, and within the
anti-type VII collagen autoantibodies the IgG4 sub-class
was the most represented. IgG4 may induce inflamma-
tion and tissue damage by activating leukocytes with a
non-complement fixing pattern or just binding collagen
VII in a Fc-independent fashion leading to dermal-
epidermal separation [35]. Although in our study we
have not identified the subclass of IgG-autoantibodies,
we observed very high levels of IgG4 among patients
with RDEB; this observation might explain the dissimilar
clinical evolution not only relative to skin manifestation,
but also in relation to extracutaneous complication, such
as organ damage.
In this study, we have also found autoantibodies against
NC-16A domain of BP180 and C- and N-terminal do-
mains of BP230. Another current model of chronic auto-
immune skin diseases predicts that “dominant” self
epitopes induce the inflammatory cascade and tissue dam-
age in the target organ. Recruitment and activation ofautoreactive T lymphocytes specific for “secondary” epi-
topes of the nominal autoantigen or non distinct self-
proteins subsequently contribute to the disease course.
This phenomenon is called epitope spreading (ES). There
is growing evidence that inter- and intramolecular ES
events are not simply an epiphenomenon but are critical
in the evolution and progression of diseases [36]. Our data
confirm this hypothesis and demonstrate that anti-type
VII collagen autoantibodies strictly correlate with BP180
and BP230 autoantibodies.
Our study could be limited by the lack of Direct
Immunofluorescence (DIF) data on skin biopsies for
detection of tissue-bound autoantibodies. We believe that
this detection, which is very important to define the role
of these autoantibodies, should be carried out by more
specific epitope-related methods rather than by fluores-
cence pattern observed with DIF.
Our opinion is that the most significant finding can
be seen in the correlation between antibodies titres and
the skin disease activity score. However, we also think
that this finding should be confirmed on a wider num-
ber of DEB patients, considering the natural history of
the disease. These correlations can also be assessed by
means of other clinical scores [37-39]. On the other
hand, the determination of anti-skin autoantibodies by
means of the ELISA method has many advantages: it
can be easily introduced in the clinical routine, it is
little traumatic for the patient, therefore repeatable,
and quantitative.
Conclusions
In this study, we have reported the presence of skin auto-
antibodies in EB patients. In particular, we revealed a high
prevalence of autoantibodies in RDEB patients. Unless the
pathogenic role of antiskin autoantibodies in patients with
DEB is demonstrated by ex vivo and experimental animals
using antibody passive transfer model, their presence can
be simply interpreted as an epiphenomenon.
Experimental models can be very useful not only to in-
vestigate the mechanism underlying pathogenetic auto-
antibody production and autoantibodies mediated tissue
injury, but also for the development of more effective
therapeutic strategies for this disease.
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